Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma

In conclusion, image evaluation strategy with RECIST for patients with lung cancer has difficulty in obtaining the appropriate quantity of diffuse lung nodules, pleural effusions, and bone metastases. The type of 4-TMpc after 14 days TKI targeted therapy is associated with image response and PFS without accounting for mutation status in advanced lung adenocarcinoma patients. Our study results could help early therapeutic decision making by identifying patients who may benefit from gefitinib, erlotinib, afatinib, crizotinib, or ceritinib 14 days after TKI targeted therapy.status, in patients with advanced lung adenocarcinoma. READ ARTICLE

PLOS ONE DOI: 10.1371/journal.pone.0240736

Authors: Chen H-J, Tu C-Y, Huang K-Y, Chien C-R, Hsia T-C

Real-World OutcomesKirk SmithDecember 11, 2020serum tumor marker, TKI